This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

7 Big-Pharma Stocks With Untapped Potential

7. Bayer (BAYRY)

Company profile: Bayer, the international German health-care and chemical conglomerate, with a market value of $63 billion, has three business units: health care, crop science; which makes pesticides and herbicides; and material science, which makes plastics materials. Health care provides half of the company's revenue and includes pharmaceuticals, vitamins, blood glucose monitors and animal-health products.

Dividend Yield: 2%

Investor takeaway: Its shares are up 28% this year and have a three-year, average annual return of 21.4%. Morningstar says Bayer "is one of the best positioned firms in emerging markets. It earned 32% of its health-care revenue from emerging markets in 2011, and recently restructured to facilitate significantly increased investment in the regions. We expect the sales contribution from emerging markets to grow to 43% by 2015."

The German company gets little U.S. analyst coverage. On July 31, it raised its 2012 revenue and earnings forecasts saying it expects revenue growth of 4% to 5% this year to about $48 billion, citing increased sales of crop chemicals and drugs as well as favorable exchange rates, which sent its shares to the highest price in more than four years.

6. AstraZeneca (AZN - Get Report)

Company profile: AstraZeneca, based in the U.K. and with a market value of $59 billion, has a product portfolio that includes gastrointestinal, cardiovascular, respiratory and neuroscience therapies. Emerging markets made up 17% of revenue last year and less than 40% of revenue comes from the U.S.

Dividend Yield: 6.04%

Investor takeaway: Its shares are up 8% this year and have a three year, average annual return of 6.2%. Analysts give its shares one "buy" rating, one "buy/hold," six "holds," and one "weak hold," according to a survey of analysts by S&P.

S&P, which has it rated "sell," says it expects 2012 sales to decline about 12% from 2011's $32.3 billion, due in part to lower sales of the proton pump inhibitor Nexium, which faces increased competition. Analysts' consensus estimate is for earnings of $5.82 per share this year, and $5.89 per share next year, a 1% increase.

5. Sanofi (SNY)

Company profile: Sanofi, of France, with a market value of $110 billion, is among the world's largest drugmakers, producing a wide range of prescription pharmaceuticals and vaccines. Emerging markets accounted for about 30% of its sales of $49 billion last year. "The company was among the first to enter Russia (1970) and China (1982) as well as several other markets," which bodes well for its long-term prospects, said Morningstar.

Dividend Yield: 3.4%

Investor takeaway: Its shares are up 18.5% this year and have a three-year, average annual return of 11.8%. Analysts give its shares three "buy" ratings, one "buy/holds," and three "holds," according to a survey of analysts by S&P. Analysts' consensus estimate is for earnings of $3.75 per share this year, rising to $3.82 per share next year.

4. Abbott (ABT - Get Report)

Company profile: Abbott, with a market value of $104 billion, offers a wide range of prescription pharmaceuticals, infant and adult nutritionals, diagnostics and medical devices. Morningstar says the company "has shot up the ranks in emerging markets through acquisitions." In 2011, it invested $4.1 billion, or 10.6%, of sales, in research and development. Foreign sales accounted for 59% of total sales in 2011.

Dividend Yield: 3.09%

Investor takeaway: Its shares are up 20% this year and have a three-year, average annual return of 17%. Analysts give its shares five "buy" ratings, five "buy/holds," 11 "holds," and one "sell," according to a survey of analysts by S&P.

S&P has it rated "buy," with a $74 price target, a 12% premium to the current price. Analysts' consensus estimate is for earnings of $5.05 per share this year, rising 6%, to $5.36 per share, next year.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
GSX $0.02 0.00%
ABT $47.11 0.71%
BMY $66.02 1.20%
AZN $70.16 0.13%
JNJ $101.67 1.30%

Markets

DOW 18,001.90 +289.24 1.63%
S&P 500 2,087.54 +26.52 1.29%
NASDAQ 4,946.3920 +55.1730 1.13%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs